Q4 2016 Dimension Therapeutics Inc Earnings and Business Update Call

9/3/2017 8:30

Conference Call Dimension Therapeutics Inc

Dimension Therapeutics Inc Conference call or earnings call will be held on Mar 9, 2017 During the earnings conference call's session Dimension Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Dimension Therapeutics Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
We are a leading gene therapy company focused on discovering and developing new therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The liver is a vital organ that plays an important role in human metabolism and key physiologic functions, and is the target organ for our initial programs: hemophilia B, hemophilia A, ornithine transcarbamylase, or OTC, deficiency, and glycogen storage disease type Ia, or GSDIa. We continue to advance our lead product candidate, DTX101, and, in January 2016, initiated dosing in our Pase I/II open-label clinical trial of DTX101 in adults with moderate/severe to severe hemophilia B.    
Read more Conference Call

Dimension Therapeutics Inc (DMTX)

840 Memorial Drive, Cambridge Massachusetts 02139, United States